An observational study in Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Recruiting at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-08-21.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational
Among 107 studies in Multiple Sclerosis by Novartis — 9 open to participants now, 25 under way, 7 of them phase 3. Multiple Sclerosis · Novartis.
Among the 107 studies in Multiple Sclerosis by Novartis, this one has the largest planned enrollment of the 41 observational ones that give a count, is one of 4 that started in 2026, is one of 41 observational ones, reaches primary completion later than 10 of the 24 other live ones, and was the 105th registered.
3,267 studies on the registry are indexed under Multiple Sclerosis; 662 are open to participants now.
Browse Multiple Sclerosis studies →9 of the 107 studies in Multiple Sclerosis by Novartis are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 33 more countries
Ages 18–65
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 16 more countries
Ages 40–70
Novartis Pharmaceuticals · Sites in Greece
Ages 18–55
Novartis Pharmaceuticals · Sites in Switzerland
Ages 18+ · Women only
Novartis Pharmaceuticals · Sites in Portugal
Ages 18–99
By country, each count listing its studies:
Of the 430 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 211 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
107 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 15 · Phase 3 24 · Phase 4 26
First in 2003; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 7,466 is above the median of 100 across 971 observational studies indexed under Multiple Sclerosis.
Median enrollment 151 across the 65 interventional studies, 312 across the 41 observational. Of the 78 that completed or were terminated, 45 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,718 studies on the registry; 221 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 438 (75%) have results posted.
6 of the studies in Multiple Sclerosis by Novartis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06847724Phase 3SandozComparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis | 2026-11 |
| NCT07821411Novartis PharmaceuticalsA Real-World Study of Ofatumumab in Multiple Sclerosis Patients in Germany and Japan | 2026-11-30 |
| NCT05776888Novartis PharmaceuticalsEarly Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years | 2026-12-16 |
| NCT07779460Novartis PharmaceuticalsA Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice | 2026-12-31 |
| NCT05809986Novartis PharmaceuticalsOfatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study | 2026-12-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 107 studies in Multiple Sclerosis by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to generate real-world evidence on the clinical effectiveness and economic burden of ofatumumab (OMB) versus ocrelizumab (OCR) in patients diagnosed with multiple sclerosis (MS) in the United States (US). Clinical effectiveness will be assessed using annualized relapse rate (ARR), while economic burden will be assessed using healthcare resource utilization (HCRU) and healthcare costs (HCC). This study will use two primary data sources that capture longitudinal, de-identified healthcare utilization derived from claims submitted for reimbursement.
Patients with MS newly initiated on OMB or OCR in real-world practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients in the pooled OMB and pooled OCR cohorts are required to meet the following eligibility criteria:
Patients in the treatment-naïve OMB and treatment-naïve OCR cohorts are required to meet the following eligibility criteria:
Exclusion criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
MS patients initiated on OMB who have not used a DMT for the treatment of MS in the 12-month period prior to index date.
MS patients initiated on OCR who have not used a DMT for the treatment of MS in the 12-month period prior to index date.
All patients diagnosed with MS initiated on OMB including treatment-naïve and -experienced patients.
All patients diagnosed with MS initiated on OCR including treatment-naïve and -experienced patients.
Annualized Relapse Rate (ARR) in Treatment-naïve MS Patients
ARR is defined as the number of relapse episodes per patient-year (PPY).
Time frame: Up to approximately 5 years, 4 months
ARR in All MS Patients
ARR is defined as the number of relapse episodes PPY.
Time frame: Up to approximately 5 years, 4 months
Number of All-cause and MS-related Healthcare Visits PPY
Healthcare visits include IP stays, IP days, emergency department (ED) visits, OP visits.
Time frame: Up to approximately 5 years, 4 months
Total All-cause and MS-related Healthcare Costs (HCC) PPY
HCC include total, IP, ED, OP, and pharmacy costs.
Time frame: Up to approximately 5 years, 4 months
Time From Treatment Initiation to First Relapse
Time frame: Up to approximately 5 years, 4 months
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Dec 2026, 8 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.